ID-119031166 is under clinical development by Yunovia and currently in Phase I for Metabolic Dysfunction-Associated Steatohepatitis (MASH). According to GlobalData, Phase I drugs for Metabolic Dysfunction-Associated Steatohepatitis (MASH) have a 71% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how ID-119031166’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

ID-119031166 overview

ID-119031166 is under development for the treatment of nonalcoholic steatohepatitis (NASH). It acts by targeting farnesoid X receptor (FXR). The therapeutic drug candidate is a new chemical synthetic drug. It is administered through oral route.

Yunovia overview

Yunovia, a subsidiary of Ildong Pharmaceutical Co Ltd, is a clinical stage pharmaceutical and drug development company. The company specializes in drug development for liver diseases, hepatocellular carcinoma, cardiovascular disease, gastrointestinal, eye disease, diabetes, brain diseases, and other major therapeutic areas with large unmet medical need. Its drug product portfolio includes FXR agonists, GPR40 agonists, GLP-1 receptor agonists, ATX inhibitor, P-CAB activator, PDE4 activator, A1 and A2A antagonists. The company service offerings include preclinical research, clinical trials, drug development, drug discovery programs, research and development. Yunovia provides its services in various therapeutic areas include liver cirrhosis treatment, reflux disease treatment, dry eye disease treatment, metabolic dysfunction-associated steatohepatitis (MASH) treatment, type 2 diabetes mellitus treatment, and parkinson’s disease (PD) treatment. Yunovia is headquartered in Hwaseong-si, Gyeonggi-do, South Korea.

For a complete picture of ID-119031166’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.